‘You have to get up on the podium’: Incoming BIO chair Paul Hastings on diversity, drug pricing and working with the FDA
Paul Hastings’ day job as CEO of Nkarta has him talking about natural killer cells and their potential applications in cancer. But throughout the pandemic you’ll likely remember him in his other role: As vice chair of BIO, the biotech trade group, he would often sign his name right under chairman (and Ovid CEO) Jeremy Levin, calling for FDA independence, standing up for the right to vote, and encouraging others to speak out.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 113,300+ biopharma pros reading Endpoints daily — and it's free.